Toronto, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) — King's Hawaiian, known for its irresistibly soft, fluffy, and signature sweet rolls, is bringing a taste of paradise to Toronto this holiday season with a limited-time pop-up at The Well. From December 18 to 21, 2025, King's Hawaiian will host a Holiday Happy Hour from 3 to […]

(NasdaqGM:RAPP), BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan

(PinkSheets:BSEM),(Pinksheets:BSEM), Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem's non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates POMPANO BEACH, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused

Washington, D.C., Dec. 18, 2025 (GLOBE NEWSWIRE) — A video presentation from Wall Street Journal bestselling author and technology analyst James Altucher is now available, offering viewers a detailed examination of Elon Musk's Starlink network and why growing industry attention has centered on the possibility of a public offering in 2026. The presentation, delivered entirely

(TSX-V:APGO),(OTC US:APGOD),(OTCQB:APGOD),(Frankfurt:6ZF.F),(OTC US:APGOF),(Other OTC:APGOF), VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo Silver” or the “Company“) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF) is pleased to announce that, through its wholly owned subsidiary, Stronghold Silver USA Corp., the Company has completed all payments required under the Option to Purchase Agreement dated December 21, 2020,

Proceeds will support the advancement of Atavistik Bio's oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs) through clinical proof of concept Atavistik Bio anticipates initiating its clinical trial in HHT in the first half of 2026 CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE)

(NYSE MKT:CATX), SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday,

(NASDAQ:NTRB),(NASDAQ:NTRBW), Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. Illicit fentanyl and its core precursor chemicals have been designated as weapons of mass destruction to enable the US government to combat the

Mahe, Seychelles, Dec. 18, 2025 (GLOBE NEWSWIRE) — With Christmas and the New Year just around the corner, BitMart, a premier global digital asset trading platform serving over 12 million users, is kicking off a festive, global Christmas carnival to thank users worldwide for their continued support. The “Merry Coin-mas, Mega Giveaways” campaign spans key

(Other OTC:ONAR),(OTC US:ONAR), Miami, FL, Dec. 18, 2025 (GLOBE NEWSWIRE) — ONAR Holding Corporation (OTCQB: ONAR) (“ONAR” or the “Company”), an AI-powered marketing platform and network of specialist agencies, today announced that it has retired approximately $311,000 of outstanding debt through a voluntary conversion into ONAR common stock by certain noteholders. The transaction reduces ONAR's